Monte Rosa Therapeutics, Inc. Common Stock
GLUEMonte Rosa Therapeutics, Inc. develops targeted protein degradation therapies aimed at treating difficult-to-drug diseases. Focused on innovative approaches, the company leverages its proprietary technologies to discover and develop novel therapeutics for unmet medical needs.
Company News
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced it will participate in two investor conferences in May and June 2026, including fireside chats at the TD Cowen Oncology Innovation Summit and Jefferies Global Healthcare Conference. The company is advancing its pipeline...
Despite a growing sentiment favoring industrial and dividend stocks in 2026, three high-risk stocks that surged over 100% in 2025 continue to show upside potential. FTAI Aviation benefits from GE Aerospace and Palantir partnerships, Kratos Defense gains from defense sector positioning, and Monte Rosa Therapeutics shows promise from positive clini...
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced pricing of an underwritten public offering of 11.125 million shares at $24.00 per share and 1.375 million pre-funded warrants, expected to raise approximately $300 million gross proceeds. The offering is expected to clo...
Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.
Monte Rosa Therapeutics announced CEO Markus Warmuth will participate in multiple healthcare investor conferences in November and December 2025, presenting the company's molecular glue degrader (MGD) research and developments.
